World-Wide Pharmaceutical Market:

• 2007: 712 billon dollars, an increase of 6.4% (all countries merged), almost 80% of this value is due to chemical-molecule drugs).
• 2008: US$ 785 billion, an increase of 4.5 to 5.5%, whilst the forecast for 2009 should surpass US $ 820 billion.

Geographic distribution:

• 41 % USA
• 20 % Europe 5 (1)
• 11 % rest of Europe
• 11 % Asia excluding Japan
• 9 % Japan
• 6 % Latin America
• 2 % Canada

Pharmaceutical Sector Increase in Sales:

• + 6.4% for the global market in 2007 and +4.5 to +5.5% in 2008
• + 4.1% for the USA in 2007, whilst the forecast for 2008 is +2%
• + 4.8 % for Europe 5 (1) in 2007
• + 3.6 % for Japan in 2007
• + 14 % for « Pharmerging markets (2) in 2007 »
  

  ---

  (1) Europe 5 : France, Germany, Italy, United Kingdom, Spain
  (2) Emerging Pharma markets (according to IMS Health report 2008) : Brazil, Russia, India, China, Turkey, Mexico, South Korea

Increase in Sales by Therapeutical Category in 2008:

• Oncology: + 13.9 %
• ACE inhibition: + 13.7 %
• Anti-diabetes: + 8.5%
• Anti-psychotics: + 10.6 %
• Anti-epileptics: + 13.4 %
• Auto-immune agents: + 19.6 %

Generic Sales Increase:

• IMS Health forecasts a 5 to 7% increase in the world in 2009.
• Generic medicines are 30 to 80% less expensive than the original brands.
• According to IMS Health, sales of US$ 135 billion will be affected by generics between 2008 and 2012.

New Chemical Entities and Market Authorisation Application:

• 17 NCEs FDA approved in 2008 as compared to 18 in 2007, 22 in 2006 and 20 in 2005.

Biotechnology Medicines: (therapeutic proteins and vaccines)

Also known as Biologics, this market represents US$ 75 billion and is dominated by the USA which holds 56%.

• Biologics represent 11% of the world-wide medicine market and 17% annual growth.
• The 2008 forecast follows the world-wide market, estimated at US$ 82 billion, an increase of only 10%.

• 42% of medicines in clinical trials are Biologics.  
• 134 Biologics have been on the market for about 15 years and 5 Biosimilars have already been authorised by the EMEA (European Medicinal Evaluation Agency) in Europe.
• 22 out of 114 Biologics acquired « blockbuster » status.
• 7 new Biologics authorised in 2007.